Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Technology Scientific & Technical Instruments
Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is... see more

Recent & Breaking News (TSXV:ARCH)

Arch Biopartners Arranges Convertible Note Financing

GlobeNewswire February 8, 2018

Arch Biopartners Announces Non Brokered Private Placement Financing

GlobeNewswire January 26, 2018

Arch Biopartners Announces Completion of GMP Manufacturing of AB569 and Start Date of Phase I Trial

GlobeNewswire December 6, 2017

Arch Biopartners Engages Nucro Technics to Begin Toxicology Studies for Metablok

GlobeNewswire November 1, 2017

Arch Biopartners Closes Convertible Note Financing

Marketwired October 24, 2017

Arch Biopartners Initiates Manufacturing Process for Metablok

MarketWire Canada October 10, 2017

Arch Biopartners' GMP Manufacturing of AB569 Progresses to Final Production Stage

MarketWire Canada September 28, 2017

Arch Biopartners Increases Non-Brokered Private Placement Financing

MarketWire Canada September 12, 2017

Arch Biopartners Provides Update on GMP Manufacturing of AB569

MarketWire Canada July 27, 2017

Arch Biopartners Retains Market Maker and Arranges Non Brokered Private Placement Financing

Marketwired July 24, 2017

Arch Biopartners Announces Start of GMP Manufacturing for AB569 at Dalton Pharma Services

MarketWire Canada May 4, 2017

Arch Biopartners' Lead Anti-Bacterial Drug Candidate AB569 to Enter Investigator-Sponsored Phase I Human Trial

MarketWire Canada April 13, 2017

Arch Biopartners Closes Non-Brokered Private Placement Financing

Marketwired February 28, 2017

Arch Biopartners Announces TSXV Stock Ticker Symbol Change to "ARCH"

MarketWire Canada February 23, 2017

Arch Biopartners Announces Non-Brokered Private Placement Financing

MarketWire Canada February 21, 2017

Arch Biopartners Appoints Patrick Vink to Board of Directors

MarketWire Canada December 12, 2016

Arch Biopartners Collaborates With Team at Cincinnati Veterans Affairs Medical Center to Prepare Phase I and II Human Trial Protocol and Application for AB569

MarketWire Canada October 27, 2016

Arch Biopartners Announces Issuance of U.S. Patent for Metablok

MarketWire Canada October 11, 2016

GRANT OF OPTIONS TO DIRECTORS

Stockhouse.com September 27, 2016

Arch Biopartners Engages Catalent to Begin Manufacturing Process for AB569

MarketWire Canada August 10, 2016